VBAS is a high-margin neurosurgery device experiencing strong revenue growth with 85% gross margins. 2025 marked a turnaround milestone with operating profit of $33,900 compared to an operating loss of $(9,145) in 2024. However, the company faces a critical liquidity challenge with a $4.15 million working capital deficiency and may lack sufficient cash through November 2026 without additional funding.
Cyborg Score Rationale
VYCO demonstrates strong product fundamentals (high gross margins, peer-reviewed clinical validation, international growth trajectory) and operating profit achievement in 2025. However, severe liquidity constraints, minimal revenue scale (~$1.86M), and substantial working capital deficiency create material near-term execution risk that overshadows the underlying product opportunity.
Top Insights
VBAS (core product) achieved 18% revenue growth in 2025 with 83% gross margins, demonstrating strong product-market fit and pricing power in minimally invasive neurosurgery
Company achieved GAAP operating profit in 2025 for first time since 2024 loss, signaling operational improvements and cost control
International markets now drive majority of growth (May 2026 update confirms continued international momentum), representing key strategic expansion lever
Critical liquidity crisis with working capital deficiency threatens near-term viability despite product strength; survival contingent on capital extension or additional funding by Q3 2026
Named Competitors
Neuromate/Stereotactic Robot Systems — Large-cap neurosurgery platforms and minimally invasive access systems
Neuro Navigation/Surgical Platforms — Broad neurosurgery device portfolio including access and retraction systems
(March 2026) 2025 full-year results: Revenue $1.86M (+17% YoY), GAAP operating profit of $33,900 vs. prior-year operating loss
(April 2025) Seven new peer-reviewed studies published on VBAS, bringing total published clinical papers to 50
(May 2026) Q1 2026 revenue $458.5K (+5% YoY), continued international growth momentum with GAAP operating income of $45.8K and net loss to common shareholders of $(142K)
Open the full interactive Vycor Medical Inc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.